Seven Fleet Capital Management LP Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

Posted by Stanley Muller on Sep 5th, 2026

Seven Fleet Capital Management LP bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 110,393 shares of the company’s stock, valued at approximately $12,924,000. Mirum Pharmaceuticals makes up about 2.1% of Seven Fleet Capital Management LP’s portfolio, making the stock its 9th biggest position. Seven Fleet Capital Management LP owned 0.17% of Mirum Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Corient Private Wealth LP acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $1,565,000. Bank of America Corp DE acquired a new position in Mirum Pharmaceuticals in the second quarter worth $65,761,000. Boone Capital Management LLC acquired a new position in Mirum Pharmaceuticals in the second quarter worth $48,659,000. Odyssean LLC increased its stake in Mirum Pharmaceuticals by 149.9% during the second quarter. Odyssean LLC now owns 29,924 shares of the company’s stock valued at $3,503,000 after purchasing an additional 17,952 shares during the last quarter. Finally, Man Group plc acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $4,353,000.

Analyst Ratings Changes

MIRM has been the topic of a number of recent research reports. Citigroup restated a “market outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Robert W. Baird set a $123.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a research note on Monday, June 15th. Finally, Royal Bank Of Canada lowered their target price on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.31.

Read Our Latest Analysis on MIRM

Mirum Pharmaceuticals Stock Up 0.3%

MIRM stock opened at $100.90 on Friday. The stock has a market cap of $6.55 billion, a PE ratio of -6.93 and a beta of 0.49. The firm’s 50-day simple moving average is $109.09 and its 200 day simple moving average is $101.73. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same quarter last year, the company posted ($0.12) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% on a year-over-year basis. As a group, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the transaction, the chief financial officer owned 36,355 shares in the company, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 133,814 shares of company stock worth $13,914,562. Company insiders own 8.32% of the company’s stock.

About Mirum Pharmaceuticals

(Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.